197 related articles for article (PubMed ID: 30831428)
1. RNA-Based Therapy Utilizing Oculopharyngeal Muscular Dystrophy Transcript Knockdown and Replacement.
Abu-Baker A; Kharma N; Perreault J; Grant A; Shekarabi M; Maios C; Dona M; Neri C; Dion PA; Parker A; Varin L; Rouleau GA
Mol Ther Nucleic Acids; 2019 Apr; 15():12-25. PubMed ID: 30831428
[TBL] [Abstract][Full Text] [Related]
2. Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation.
Davies JE; Sarkar S; Rubinsztein DC
Hum Mol Genet; 2008 Apr; 17(8):1097-108. PubMed ID: 18178579
[TBL] [Abstract][Full Text] [Related]
3. BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy.
Strings-Ufombah V; Malerba A; Kao SC; Harbaran S; Roth F; Cappellari O; Lu-Nguyen N; Takahashi K; Mukadam S; Kilfoil G; Kloth C; Roelvink P; Dickson G; Trollet C; Suhy D
Mol Ther Nucleic Acids; 2021 Jun; 24():67-78. PubMed ID: 33738139
[TBL] [Abstract][Full Text] [Related]
4. Study of a Taiwanese family with oculopharyngeal muscular dystrophy.
Kuo HC; Chen CM; Lee-Chen GJ; Hu FJ; Chu CC; Liou CW; Huang CC
J Neurol Sci; 2009 Mar; 278(1-2):21-4. PubMed ID: 19101703
[TBL] [Abstract][Full Text] [Related]
5. Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy.
Roth F; Dhiab J; Boulinguiez A; Mouigni HR; Lassche S; Negroni E; Muraine L; Marhic A; Oliver A; Lainé J; Rouche A; O'Ferrall EK; van Engelen B; Ottenheijm C; Greif H; Blumen S; Lacau St Guily J; Perie S; Butler-Browne G; Mouly V; Trollet C
Acta Neuropathol; 2022 Dec; 144(6):1157-1170. PubMed ID: 36197469
[TBL] [Abstract][Full Text] [Related]
6. Functional impact of an oculopharyngeal muscular dystrophy mutation in PABPN1.
García-Castañeda M; Vega AV; Rodríguez R; Montiel-Jaen MG; Cisneros B; Zarain-Herzberg A; Avila G
J Physiol; 2017 Jul; 595(13):4167-4187. PubMed ID: 28303574
[TBL] [Abstract][Full Text] [Related]
7. Nuclear speckles are involved in nuclear aggregation of PABPN1 and in the pathophysiology of oculopharyngeal muscular dystrophy.
Bengoechea R; Tapia O; Casafont I; Berciano J; Lafarga M; Berciano MT
Neurobiol Dis; 2012 Apr; 46(1):118-29. PubMed ID: 22249111
[TBL] [Abstract][Full Text] [Related]
8. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1.
Chartier A; Benoit B; Simonelig M
EMBO J; 2006 May; 25(10):2253-62. PubMed ID: 16642034
[TBL] [Abstract][Full Text] [Related]
9. PABPN1 gene therapy for oculopharyngeal muscular dystrophy.
Malerba A; Klein P; Bachtarzi H; Jarmin SA; Cordova G; Ferry A; Strings V; Espinoza MP; Mamchaoui K; Blumen SC; St Guily JL; Mouly V; Graham M; Butler-Browne G; Suhy DA; Trollet C; Dickson G
Nat Commun; 2017 Mar; 8():14848. PubMed ID: 28361972
[TBL] [Abstract][Full Text] [Related]
10. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy.
Fan X; Messaed C; Dion P; Laganiere J; Brais B; Karpati G; Rouleau GA
Can J Neurol Sci; 2003 Aug; 30(3):244-51. PubMed ID: 12945950
[TBL] [Abstract][Full Text] [Related]
11. PABPN1 loss-of-function causes APA-shift in oculopharyngeal muscular dystrophy.
Shademan M; Mei H; van Engelen B; Ariyurek Y; Kloet S; Raz V
HGG Adv; 2024 Apr; 5(2):100269. PubMed ID: 38213032
[TBL] [Abstract][Full Text] [Related]
12. Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.
Vest KE; Phillips BL; Banerjee A; Apponi LH; Dammer EB; Xu W; Zheng D; Yu J; Tian B; Pavlath GK; Corbett AH
Hum Mol Genet; 2017 Sep; 26(17):3235-3252. PubMed ID: 28575395
[TBL] [Abstract][Full Text] [Related]
13. Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death.
Fan X; Dion P; Laganiere J; Brais B; Rouleau GA
Hum Mol Genet; 2001 Oct; 10(21):2341-51. PubMed ID: 11689481
[TBL] [Abstract][Full Text] [Related]
14. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies.
Abu-Baker A; Rouleau GA
Biochim Biophys Acta; 2007 Feb; 1772(2):173-85. PubMed ID: 17110089
[TBL] [Abstract][Full Text] [Related]
15. Proteomic analysis reveals that wildtype and alanine-expanded nuclear poly(A)-binding protein exhibit differential interactions in skeletal muscle.
Banerjee A; Phillips BL; Deng Q; Seyfried NT; Pavlath GK; Vest KE; Corbett AH
J Biol Chem; 2019 May; 294(18):7360-7376. PubMed ID: 30837270
[TBL] [Abstract][Full Text] [Related]
16. Expression of the polyalanine expansion mutant of nuclear poly(A)-binding protein induces apoptosis via the p53 pathway.
Bhattacharjee RB; Zannat T; Bag J
Cell Biol Int; 2012 Aug; 36(8):697-704. PubMed ID: 22519734
[TBL] [Abstract][Full Text] [Related]
17. An Antibody to Detect Alanine-Expanded PABPN1: A New Tool to Study Oculopharyngeal Muscular Dystrophy.
Vest KE; Apponi LH; Banerjee A; Pavlath GK; Corbett AH
J Neuromuscul Dis; 2015 Oct; 2(4):439-446. PubMed ID: 27858752
[TBL] [Abstract][Full Text] [Related]
18. Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy.
Davies JE; Rose C; Sarkar S; Rubinsztein DC
Sci Transl Med; 2010 Jun; 2(34):34ra40. PubMed ID: 20519718
[TBL] [Abstract][Full Text] [Related]
19. A Case of Oculopharyngeal Muscular Dystrophy Caused by a Novel PABPN1 c.34G > T (p.Gly12Trp) Point Mutation without Polyalanine Expansion.
Takahashi Y; Morimoto N; Nada T; Morimoto M; Eura N; Minami N; Nishino I
J Neuromuscul Dis; 2023; 10(3):459-463. PubMed ID: 36847015
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial localization of PABPN1 in oculopharyngeal muscular dystrophy.
Doki T; Yamashita S; Wei FY; Hara K; Yamamoto T; Zhang Z; Zhang X; Tawara N; Hino H; Uyama E; Kurashige T; Maruyama H; Tomizawa K; Ando Y
Lab Invest; 2019 Nov; 99(11):1728-1740. PubMed ID: 30894671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
